TAZVYNDA Trademark

Trademark Overview

On Thursday, August 3, 2017, a trademark application was filed for TAZVYNDA with the United States Patent and Trademark Office. The USPTO has given the TAZVYNDA trademark a serial number of 87554277. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 15, 2021. This trademark is owned by Epizyme, Inc.. The TAZVYNDA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products, namely, EZH2 inhibitory drugs
tazvynda

General Information

Serial Number87554277
Word MarkTAZVYNDA
Filing DateThursday, August 3, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 15, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 12, 2017

Trademark Statements

Goods and Servicespharmaceutical products for the prevention and treatment of cancer; pharmaceutical products, namely, EZH2 inhibitory drugs

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 8, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEpizyme, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameEpizyme, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Wednesday, October 19, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, March 15, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 15, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, August 15, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 14, 2020SOU EXTENSION 5 GRANTED
Friday, July 24, 2020SOU EXTENSION 5 FILED
Wednesday, August 12, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 24, 2020TEAS EXTENSION RECEIVED
Wednesday, January 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 27, 2020SOU EXTENSION 4 GRANTED
Monday, January 27, 2020SOU EXTENSION 4 FILED
Monday, January 27, 2020TEAS EXTENSION RECEIVED
Wednesday, July 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 22, 2019SOU EXTENSION 3 GRANTED
Monday, July 22, 2019SOU EXTENSION 3 FILED
Monday, July 22, 2019TEAS EXTENSION RECEIVED
Thursday, January 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 15, 2019SOU EXTENSION 2 GRANTED
Tuesday, January 15, 2019SOU EXTENSION 2 FILED
Tuesday, January 15, 2019TEAS EXTENSION RECEIVED
Saturday, June 16, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 14, 2018SOU EXTENSION 1 GRANTED
Thursday, June 14, 2018SOU EXTENSION 1 FILED
Thursday, June 14, 2018TEAS EXTENSION RECEIVED
Tuesday, February 6, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 12, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 12, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, November 6, 2017ASSIGNED TO EXAMINER
Tuesday, August 8, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 7, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

tazvynda pharmaceutical products inhibitory drugs namely treatment prevention cancer